Get the Stockscreener App
45.37
1.24%
-0.57
Moderna Inc stock is traded at $45.37, with a volume of 10.21M.
It is down -1.24% in the last 24 hours and down -9.31% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$45.94
Open:
$46.635
24h Volume:
10.21M
Relative Volume:
1.24
Market Cap:
$17.99B
Revenue:
$1.94B
Net Income/Loss:
$-2.82B
P/E Ratio:
-6.2478
EPS:
-7.2617
Net Cash Flow:
$-2.08B
1W Performance:
-10.57%
1M Performance:
-9.31%
6M Performance:
+67.05%
1Y Performance:
+67.85%
1-Day Range:
$43.68
$48.40
1-Week Range:
$43.68
$51.36
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
45.37 | 17.99B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals - Yahoo Finance
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges By GuruFocus - Investing.com Canada
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges - GuruFocus
Moderna (MRNA) Reports Strong Q1 2026 Performance with $400 Million Revenue - GuruFocus
Moderna, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Legal settlement drives Q1 2026 loss at Moderna (NASDAQ: MRNA) - Stock Titan
Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales - The Economic Times
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. - Barron's
Sector Update: Health Care Stocks Softer Friday Afternoon - Moomoo
Moderna, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MRNA) 2026-05-01 - Seeking Alpha
Moderna’s first quarter 2026 sales well ahead of estimates - The Pharma Letter
RBC Capital raises Moderna stock price target on Q1 beat By Investing.com - Investing.com Canada
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales - The Globe and Mail
Moderna sees revenue bump from international COVID vaccine sales - BioPharma Dive
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings - Proactive financial news
[144] Moderna, Inc. SEC Filing - Stock Titan
BofA raises Moderna stock price target to $32 on Q1 beat - Investing.com India
Moderna Sales Triple To $389 Million As Shares Rise 5.4% - GuruFocus
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook - Seeking Alpha
Why Is Moderna Stock Falling Friday?Moderna (NASDAQ:MRNA) - Benzinga
Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates - marketscreener.com
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround - TechStock²
Moderna beats revenue expectations with $389M, but litigation dogs earnings - BioSpace
Moderna Q1 Earnings Call Highlights - MarketBeat
Moderna tops revenue estimates on stronger international COVID vaccine sales - Yahoo! Finance Canada
Moderna Q1 2026 slides: revenue surges 260%, litigation weighs By Investing.com - Investing.com India
Transcript : Moderna, Inc., Q1 2026 Earnings Call, May 01, 2026 - marketscreener.com
Moderna Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Moderna Q1 2026 revenue beats expectations By Investing.com - Investing.com India
Earnings call transcript: Moderna Q1 2026 revenue beats expectations - Investing.com
Moderna Q1 2026 earnings beat on international COVID vaccine sales - Yahoo Finance
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates - Investing News Network
Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars - Yahoo Finance
Moderna (MRNA) Stock Jumps 8% After Q1 Earnings Beat - CoinCentral
Moderna Up Over 6% in Pre-Market Trading - Moomoo
MRNA Stock Rises Pre-Market: Moderna Bets On US Comeback With Flu Vaccine Pipeline - Stocktwits
Moderna beats Q1 estimates and reaffirms full-year guidance - Sherwood News
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Moderna Inc (NASDAQ:MRNA) Surges Past Q1 Estimates on International Strength - ChartMill
Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL) - marketscreener.com
Moderna beats revenue expectations despite wider loss - Investing.com
Moderna Q1 Loss Widens, Revenue Rises; Reiterates 2026 Revenue Outlook - marketscreener.com
Moderna stock jumps after Q1 2026 beat (MRNA:NASDAQ) - Seeking Alpha
Moderna: Q1 Earnings Snapshot - KING5.com
EU clears Moderna's flu-COVID shot as Q1 loss hits $1.3B - Stock Titan
Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimat - The Economic Times
Earnings Flash (MRNA) Moderna Posts Q1 Loss $3.40 a Share, vs. FactSet Est of $4.45 Loss - marketscreener.com
Moderna reports Q1 EPS of $ -3.40 - marketscreener.com
Moderna Reports Higher Revenue but Posts a Loss - WSJ
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Option Exercise |
30.96 |
13,885 |
429,880 |
73,574 |
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Sale |
52.29 |
13,885 |
726,047 |
59,689 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):